Jeff Castelli - 21 Dec 2022 Form 3 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role: Chief Development Officer
Signature: /s/ Christian Formica, Attorney-in-Fact
Issuer symbol: FOLD
Transactions as of: 21 Dec 2022
Net transactions value: $0
Form type: 3
Filing time: 30 Dec 2022, 20:12:30 UTC
Next filing: 04 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	FOLD	Common Stock						304,255	21 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	FOLD	Stock Options (right to buy)							21 Dec 2022	Common Stock	50,000	$12.28	Direct	F2
holding	FOLD	Stock Options (right to buy)							21 Dec 2022	Common Stock	50,000	$9.03	Direct	F2
holding	FOLD	Stock Options (right to buy)							21 Dec 2022	Common Stock	39,762	$15.67	Direct	F2
holding	FOLD	Stock Options (right to buy)							21 Dec 2022	Common Stock	82,644	$10.04	Direct	F3
holding	FOLD	Stock Options (right to buy)							21 Dec 2022	Common Stock	107,575	$9.55	Direct	F4
holding	FOLD	Stock Options (right to buy)							21 Dec 2022	Common Stock	46,396	$21.78	Direct	F5
holding	FOLD	Stock Options (right to buy)							21 Dec 2022	Common Stock	108,266	$12.11	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 161,910 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Amicus common stock.
F2	All of the options in this row are fully vested and exercisable as of December 21, 2022.
F3	The options reported in this row were granted on January 2, 2019 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 80,896 of such options were fully vested and exercisable and 1,748 remained unvested.
F4	The options reported in this row were granted on January 2, 2020 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 78,436 of such options were fully vested and exercisable and 29,139 remained unvested.
F5	The options reported in this row were granted on January 4, 2021 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 22,225 of such options were fully vested and exercisable and 24,171 remained unvested.
F6	The options reported in this row were granted on January 3, 2022 and will become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 0 of such options were fully vested and exercisable and 108,266 remained unvested.